Tianeptine

ApprovedSmall molecule

Pfizer

Tianeptine is one of 95 small molecule programs targeting Breast Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

Major Depressive DisorderActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tianeptine

Pfizer

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Tecentriq

Roche

Preclinical

36 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

MS Contin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

COVID-19

NCT06012552

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder

Completed·SSamsung Medical Center·Phase 4·NCT01309776·164 enrolled

Breast Cancer1 trial

The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.

Completed·NNational Cancer Institute, Egypt·N/A·NCT05935059·90 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT04446039·370,212 enrolled

Medication1 trial

Brain Response to Serotonergic Medications in ASD

Unknown status·KKing's College London·N/A·NCT04145076·100 enrolled

COVID-191 trial

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.

Recruiting·MMilitary Institute od Medicine National Research Institute·Phase 2·NCT06012552·140 enrolled

1 more indication

Bipolar Depression1 trial

Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT00879372·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tianeptine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tianeptine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tianeptine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Tianeptine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Major Depressive Disorder1 trial

Breast Cancer1 trial

Cohort Study1 trial

Medication1 trial

COVID-191 trial

Bipolar Depression1 trial

References

Drug Info

Quick Facts

Related News